aTyr Pharma rises on 'orphan drug' tag for lead drug in Europe

aTyr Pharma

18/01/2023 15:26

** Shares of drug developer aTyr Pharma Inc  LIFE.O  up 1.3%
at $2.32 
    ** Co says its lead experimental drug to treat a type of
inflammatory disease has been granted "orphan drug" status by
the European Commission 
    ** The drug candidate, efzofitimod, is being tested for the
treatment of sarcoidosis - LIFE   
    ** Sarcoidosis is an immune-mediated disease characterized
by clumps of inflammatory cells in one or more organs of the
body, predominantly in the lungs
    ** The "orphan" designation is assigned to a medicine
intended for use against a life-threatening or chronically
debilitating condition that affects fewer than five in 10,000
persons in the EU
    ** Including session moves, LIFE has fallen ~65% in the past
12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))